Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioStem TechnologiesBSEM -4.50%36 3-1 Month Momentum % is -18.90% as of Aug. 12, 2026. GuruFocus rates BSEM with a GF Score™ of 36/100. The stock has 3 warning signs investors should review. Among 1,386 Biotechnology companies, BioStem Technologies ranks worse than 69.48% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-12), BioStem Technologies's 3-1 Month Momentum % is -18.90%.
The industry rank for BioStem Technologies's 3-1 Month Momentum % or its related term are showing as below:
BSEM's 3-1 Month Momentum % is ranked worse than 69.48% of 1386
companies
in the Biotechnology industry
Industry Median: -7.05
vs BSEM: -18.90
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
BioStem Technologies 3-1 Month Momentum % Related Terms
BSEM vs RNTX, SPRO, ACRV: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, BioStem Technologies's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies (BSEM) has a 3-1 Month Momentum % of -18.90% as of Aug. 12, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BioStem Technologies and its competitors. According to the industry distribution chart, BioStem Technologies ranks #963 out of 1386 companies in the Biotechnology industry, placing it in the top 69.5%.
Is BioStem Technologies' 3-1 Month Momentum % too high?
BioStem Technologies' current 3-1 Month Momentum % is -18.90%. Based on the distribution chart, BioStem Technologies ranks #963 out of 1386 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioStem Technologies has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' 3-1 Month Momentum % compare to RNTX and SPRO?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #963 out of 1386 companies for 3-1 Month Momentum %. This places BioStem Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BioStem Technologies and its competitors. BioStem Technologies's current 3-1 Month Momentum % is -18.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
BioStem Technologies (BSEM) has a current 3-1 Month Momentum % of -18.90%. The current 3-1 Month Momentum % is -18.90%. BioStem Technologies' overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current 3-1 Month Momentum % is -18.90% as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
36GF Score
Get the complete analysis for BSEM
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
